The media and sera market is changing due to the introduction of serum-free media and protein-free media. The revolution in cell culture techniques is taking the research to commercial-scale processes. R&D spending, along with increasing competition, new products, the international marketplace and a changing customer base (due to the use of serum-free media) are contributing to the creation of a new kind of market in this field.
This updated BCC study looks at almost all the factors governing the market for media, sera and reagents used in cell culture. The use of serum extenders, serum alternatives, and especially the use of serum-free and protein-free media, have enhanced changes in the market. This report discusses the strengths and weaknesses of the market in light of new products, growing competition and changing customer needs.
The study provides an overview of the media, sera and reagents used in cell culture and details the present and future scenarios for media, sera and reagents. The basic principles underlying what media and sera are, their composition, and the use of reagents in cell culture also are discussed. Companies selling these products are highlighted as well as the factors affecting markets for these products, and how those markets are likely to change.
BCC presents a comprehensive analysis of the current U.S. market and the future direction in media, sera and reagents for cell culture, with the emphasis on newer products.
The report provides coverage of:
- The major types of media, sera and reagents in cell culture used in the biotech industry
- Technological issues and the latest trends and developments
- Existing and new product lines
- The growth by acquisition strategies and the collaborations by companies to increase sales and develop better and newer products
- Sales estimates, market projections through 2008 and market share information
- Government regulation.
A comprehensive literature and patent search was conducted. The literature included technical newsletters and journals, as well as many other sources. The data was collected through interviews/mails of various pharmaceutical and biotech companies. This data was complied and the projections were based on such estimates as the current number of end users, potential end users, likely unit prices, rates of consumption and the market trends.
BCC surveyed many companies to obtain data for this study. Included were the manufacturers and the end users of the drug delivery systems. We gathered the data from these industries, also spoke with officials of these industries, consulted newsletters, company literature, product literature, a host of technical articles, journals, indexes, and abstracts. Exhaustive investigations of databases by key terminology were done. In addition, we compiled data from current financial and trade information and government sources.
Shalini Shahani is a young and enterprising scientist and holds a Masters degree in Pharmaceutical Chemistry. Among the research topics she has covered are: Studies on Compounds of Potential and Pharmaceutical Interest from Ibuprofen and 2-Naphthyl Acetic acid. Shahani was awarded a Gold medal by the Prime Minister of India for her work and has worked with top companies in India and in the U.S. Some of her other reports with BCC are "Reagents of Chromatography", "Spectroscopy, an Enduring Market" and "Advanced Drug Delivery Systems".
Report Code: BIO014D, Published: October 2003, Analyst: Shalini Shahani
